AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00981-07v1
51/12/4531    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maciá, M. D.
Right arrow Articles by Oliver, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maciá, M. D.
Right arrow Articles by Oliver, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4531-4532, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00981-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Increased Susceptibility to Colistin in Hypermutable Pseudomonas aeruginosa Strains from Chronic Respiratory Infections{triangledown}


   LETTER
Top
 LETTER
REFERENCES
 
A common feature of Pseudomonas aeruginosa chronic respiratory infections (CRI), including those occurring in patients suffering from cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease, is a very high prevalence (30 to 60%) of hypermutable (or mutator) strains deficient in the DNA mismatch repair (MMR) system, in contrast to what is observed in acute processes (<1%) (1, 4, 10, 13, 14). The presence of hypermutable strains has been found to be linked to the high antibiotic resistance rates of P. aeruginosa clinical isolates recovered from patients with CRI (1, 10, 13), and in vitro and in vivo experiments have shown that hypermutation dramatically speeds up resistance development during exposure to antimicrobial agents (15, 16).

Colistin has reemerged in the last decade as a relevant therapeutic option for the treatment of infections caused by multidrug-resistant gram-negative bacteria (8). The objective of this work was to assess the activity of this antibiotic against hypermutable P. aeruginosa strains isolated from patients with CRI. Colistin susceptibility was determined by the Etest method, recently shown to be reliable for this purpose (3), in a collection of 97 P. aeruginosa isolates characterized in two previous studies (9, 10). This collection included one to four isolates recovered between 2003 and 2004 from each of 51 patients suffering from cystic fibrosis (n = 21), bronchiectasis (n = 22), or chronic obstructive pulmonary disease (n = 8). Each patient was shown to be chronically infected by a different P. aeruginosa clone, and of the 97 isolates, 43 were found to be hypermutable (most of them defective in the MMR gene mutS); a marked association between hypermutation and multidrug resistance was also documented when susceptibility to the commonly used antipseudomonal agents ceftazidime, imipenem, meropenem, ciprofloxacin, and tobramycin was analyzed in this collection (7, 8). Finally, a collection of 50 P. aeruginosa clinical isolates recovered from 50 patients admitted to our intensive care unit (ICU) between 2002 and 2003 was also tested for comparative purposes. None of these isolates was hypermutable, and each of them belonged to a different clonal type, as documented in a previous study (4). P. aeruginosa strain ATCC 27853 was used for quality control, yielding an MIC of 1 µg/ml, which falls within the acceptable range defined by the Clinical and Laboratory Standards Institute.

The distribution of the colistin MICs obtained for the hypermutable and nonhypermutable isolates from patients with CRI and the nonhypermutable isolates from ICU patients is shown in Fig. 1. In contrast to what was previously documented for other antimicrobial agents, MICs tended to be highest for ICU isolates (geometric mean MIC, 2.0 µg/ml) and lowest for hypermutable isolates from patients with CRI (0.48 µg/ml). Nonhypermutable isolates from patients with CRI showed an intermediate distribution of MICs (geometric mean MIC, 0.92 µg/ml). For only one of the strains (from the ICU isolate group) did the MICs surpass the currently recommended susceptibility breakpoint (≤4 µg/ml) (6). Statistical analysis (Mann-Whitney U test) of the distribution of the MICs yielded significant differences (P < 0.001) when hypermutable and nonhypermutable isolates from patients with CRI were compared; statistically significant differences (P < 0.001) were also obtained when nonhypermutable isolates from ICU and CRI patients were analyzed. Increased colistin susceptibility of the hypermutable strains was not likely a direct consequence of the inactivation of the MMR system since the MICs for reference strain PAO1 and its mutS-deficient derivative PAO{Delta}mutS (15) were found to be essentially identical (2 µg/ml).


Figure 1
View larger version (14K):
[in this window]
[in a new window]

  		FIG. 1. Distribution of the MICs of colistin for hypermutable P. aeruginosa strains isolated from patients with CRI (n = 43), nonhypermutable P. aeruginosa strains isolated from patients with CRI (n = 54), and nonhypermutable P. aeruginosa strains isolated from ICU patients (n = 50).

 
It is noteworthy that almost none of the patients had ever been treated with colistin (which was only seldom used in our hospital until very recently), and therefore the documented distributions are expected to reflect those naturally occurring in the absence of the selective pressure exerted by antimicrobial therapy. It is known that P. aeruginosa undergoes an intense genetic adaptation process during the establishment of CRI, in which mutations leading to the loss of function of multiple genes are positively selected (17). Whereas hypermutation may favor the persistence of CRI by facilitating the acquisition of adaptive mutations, natural hypermutable strains often end up showing reduced in vitro and in vivo fitness, probably due to the unavoidable accumulation of deleterious mutations for secondary environments (7, 11, 12). Whether the observed colistin-hypersusceptibility of natural hypermutable strains is determined by the acquisition of particular adaptive mutations, such as those leading to the frequently modified lipopolysaccharide structure of CRI isolates (2, 5), or simply by the accumulation of deleterious mutations remains to be elucidated. Although results from this work would certainly argue in favor of the use of colistin for attempting to counterselect hypermutable strains in CRI, they should be taken cautiously, since development of resistance to this agent under selective pressure is not unexpected (6), although in vitro experiments have suggested that it may occur to a lesser extent compared with other antipseudomonal agents (15).


   ACKNOWLEDGMENTS
 
This work was supported by the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, through the Spanish Network for Research in Infectious Diseases (REIPI C03/14 and RD06/0008).


   FOOTNOTES
 
{triangledown} Published ahead of print on 24 September 2007. Back


   REFERENCES
Top
 LETTER
 REFERENCES
 

  1. Ciofu, O., B. Riis, T. Pressler, H. E. Poulsen, and N. Hoiby. 2005. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49:2276-2282.[Abstract/Free Full Text]
  2. Ernst, R. K., E. C. Yi, L. Guo, K. B. Lim, J. L. Burns, M. Hackett, and S. I. Miller. 1999. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286:1561-1565.[Abstract/Free Full Text]
  3. Goldstein, F. W., A. Ly, and M. D. Kitzis. 2007. Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin. J. Antimicrob. Chemother. 59:1039-1040.[Free Full Text]
  4. Gutiérrez, O., C. Juan, J. L. Pérez, and A. Oliver. 2004. Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob. Agents Chemother. 48:3573-3575.[Abstract/Free Full Text]
  5. Hancock, R. E. W., L. M. Mutharia, L. Chan, R. P. Darveau, D. P. Speert, and G. B. Pier. 1983. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect. Immun. 42:170-177.[Abstract/Free Full Text]
  6. Hogardt, M., S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann. 2004. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 54:1057-1061.[Abstract/Free Full Text]
  7. Hogardt, M., C. Hoboth, S. Schmoldt, C. Henke, L. Bader, and J. Heessemann. 2007. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 195:70-80.[CrossRef][Medline]
  8. Li, J., R. L. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, C. R. Rayner, and D. L. Paterson. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.[CrossRef][Medline]
  9. Maciá, M. D., N. Borrell, J. L. Perez, and A. Oliver. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob. Agents Chemother. 48:2665-2672.[Abstract/Free Full Text]
  10. Maciá, M. D., D. Blanquer, B. Togores, J. Sauleda, J. L. Pérez, and A. Oliver. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386.[Abstract/Free Full Text]
  11. Mena, A., M. D. Maciá, N. Borrell, B. Moya, T. de Francisco, J. L. Pérez, and A. Oliver. 2007. Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. J. Bacteriol. 189:3665-3668.[Abstract/Free Full Text]
  12. Montanari, S., A. Oliver, P. Salerno, A. Mena, G. Bertoni, B. Tummler, L. Cariani, M. Conese, G. Doring, and A. Bragonzi. 2007. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153:1445-1454.[Abstract/Free Full Text]
  13. Oliver, A., R. Cantón, P. Campo, F. Baquero, and J. Blázquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253.[Abstract/Free Full Text]
  14. Oliver, A., F. Baquero, and J. Blazquez. 2002. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol. Microbiol. 43:1641-1650.[CrossRef][Medline]
  15. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blázquez. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.[Abstract/Free Full Text]
  16. Plasencia, V., N. Borrell, M. D. Maciá, B. Moya, J. L. Pérez, and A. Oliver. 2007. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob. Agents Chemother. 51:2574-2581.[Abstract/Free Full Text]
  17. Smith, E. E., D. G. Buckley, Z. Wu, C. Saenphimmachack, L. R. Hoffman, D. A. D'Argenio, S. I. Miller, B. W. Ramsey, D. P. Speert, S. M. Moskowitz, J. L. Burns, R. Kaul, and M. V. Olson. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. USA 103:8487-8492.[Abstract/Free Full Text]
M. D. Maciá
A. Mena
N. Borrell
J. L. Pérez
A. Oliver*
Servicio de Microbiología and Unidad de Investigación
Hospital Son Dureta
C. Andrea Doria No. 55
Instituto Universitario de Investigación en Ciencias de la Salud (IUNICS)
Palma de Mallorca, Spain

* Phone: 34 971 175 185 Fax: 34 971 175 185 E-mail: aoliver{at}hsd.es

Antimicrobial Agents and Chemotherapy, December 2007, p. 4531-4532, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00981-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00981-07v1
51/12/4531    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maciá, M. D.
Right arrow Articles by Oliver, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maciá, M. D.
Right arrow Articles by Oliver, A.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS